News
HURA
1.330
-4.32%
-0.060
TuHURA Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 1h ago
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
Benzinga · 1h ago
TuHURA Biosciences: Buy Rating Reaffirmed as Liquidity Supports Growth and $10 Price Target Remains Unchanged
TipRanks · 1h ago
Weekly Report: what happened at HURA last week (1109-1113)?
Weekly Report · 1d ago
Analysts Are Bullish on These Healthcare Stocks: TuHURA Biosciences (HURA), Kiora Pharmaceuticals (KPRX)
TipRanks · 2d ago
TuHURA Biosciences reports Q3 results
Seeking Alpha · 3d ago
TuHURA Biosciences reports Q3 EPS (10c) vs. (14c) last year
TipRanks · 4d ago
Weekly Report: what happened at HURA last week (1102-1106)?
Weekly Report · 11/09 10:20
TuHURA Biosciences Borrows Additional Funds Under Credit Facility
TipRanks · 11/06 22:35
TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition
PR Newswire · 11/04 14:15
Weekly Report: what happened at HURA last week (1026-1030)?
Weekly Report · 11/02 10:20
TuHURA Biosciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 10/27 16:53
Analysts Offer Insights on Healthcare Companies: TuHURA Biosciences (HURA) and Nuvectis Pharma (NVCT)
TipRanks · 10/27 16:50
HC Wainwright & Co. Reiterates Buy on TuHURA Biosciences, Maintains $10 Price Target
Benzinga · 10/27 16:43
TuHURA Reports Initial Data Showing Partial Responses In First Three Metastatic Merkel Cell Carcinoma Patients Treated With Ifx-2.0 Plus Keytruda
Benzinga · 10/26 11:35
TuHURA Biosciences reports initial data from study of IFx-2.0
TipRanks · 10/26 11:35
TuHURA Biosciences Provides First Look at Data from its Open-Label Study of IFx-2.0 as an Adjunctive Therapy to Keytruda® in First Line Treatment of Patients with Deep Seated Metastatic Merkel Cell Carcinoma
PR Newswire · 10/26 11:30
Weekly Report: what happened at HURA last week (1019-1023)?
Weekly Report · 10/26 10:20
Weekly Report: what happened at HURA last week (1012-1016)?
Weekly Report · 10/19 10:20
TuHURA Biosciences Adds Borrowing Under Credit Facility
TipRanks · 10/16 21:30
More
Webull provides a variety of real-time HURA stock news. You can receive the latest news about TuHURA Biosciences through multiple platforms. This information may help you make smarter investment decisions.
About HURA
TuHURA Biosciences, Inc. is a Phase III registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. Its lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It has initiated a single randomized placebo-controlled Phase III registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) compared to Keytruda plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. It is leveraging its Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies. It is also focused on the novel VISTA inhibiting mAb, known as TBS-2025.